Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 46

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 46
---
 beta glucan as an immune booster starting in Q2 2025.                                  
 ──────────────────────────────────────────────────────────────────────────────────────────────────

Production

The Company’s dedicated production team successfully
responded to the growing market demand for the cosmeceutical base business by producing over 200 metric tons of active ingredients in
2024. As part of its ordinary course operations, the Company successfully passed audits conducted by three major customers at its Edmonton
facility and received renewal of its site licence from the Health Canada Natural Product Directorate for a period of two years, which
enables the Company to manufacture, package, label, release and distribute final products.

Specialized Skill and Knowledge

The Company has a broad range of expertise in natural
product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients,
biopharmaceuticals and drug-delivery solutions. The Company relies on its employee base whose skills and knowledge are critical to maintaining
its success and always strives to identify and retain key employees in order to be competitive with compensation and working conditions.

The Company has entered into limited life licence
agreements for exclusive rights to new technologies. As part of the licence agreements, the Company works to develop and scale up the
new technologies with the goal of commercializing the technologies or products derived from such technologies. The development of these
new technologies is a costly, complex and time-consuming process, and the investment in this development often involves a prolonged time
period until a return is achieved on the investment. The Company’s ability to successfully develop and scale-up new technologies
within the expiry periods of the licence agreements is dependent on a number of key factors such as hiring and retaining employees who
have specialized knowledge and expertise pertaining to the development of the technologies, being able to access third party specialists,
being able to source key equipment or supplies in a timely manner, and delays in research and development programs related to products
derived from the technologies. Commercial success depends on many factors including the degree of innovation of the products developed,
access to funding for scale-up opportunities, uncertainties inherent in the regulatory approval processes, delays in manufacturing or
marketing arrangements, and sufficient support from strategic partners if applicable.

  33  

Competitive Conditions

The Company’s competitive success depends,
in part, on its ability to obtain and maintain patents and trademarks and to secure and protect trade secrets, proprietary technology
and manufacturing processes, and other intellectual property rights either developed internally or acquired, and to operate